46 results about "Transplant cell" patented technology

The invention discloses a bionic nanofiber-hydrogel composite biological scaffold as well as a preparation method and application thereof. The bionic nanofiber-hydrogel composite biological scaffold is a composite scaffold for simulating a gray-white matter partition structure of a spinal cord tissue, and comprises bionic nanofibers and a bionic hydrogel material, wherein the bionic nanofibers are arranged in an oriented manner and simulate a white matter ordered structure around the spinal cord, and the bionic hydrogel material is combined with the bionic nanofibers and simulates gray matter in the center of the spinal cord. According to the bionic nanofiber-hydrogel composite biological scaffold, the biological activity of loaded stem cells or adult cells can be improved, the problem that a large number of transplanted exogenous cells die due to unbalanced oxidative stress generated after tissue damage can be solved, and it is guaranteed that the transplanted cells reside in a damaged area and play a role; therefore, the spinal cord microenvironment is improved, proliferation and differentiation of endogenous neural stem cells are promoted, functional recovery after spinal cord injury is finally promoted, and great potential is achieved in spinal cord injury treatment.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

The present disclosure relates to methods of treating, preventing, or modulating diabetes in a patient in need thereof using a device for transplanting cells into a host body, specifically a method of treating diabetes in a patient in need thereof, comprising: implanting a device in the patient, wherein the device comprises: a porous scaffold comprising an immunologically compatible polymer mesh forming the walls of at least one chamber, an opening at either or both of a proximal end and a distal end of the chamber, at least one removable, non-porous plug configured to be positioned within the lumen of the at least one chamber, maintaining the device in the patient's body until the device is infiltrated with vascular and connective tissues; and infusing the chamber with cells, wherein at least some of the cells express insulin

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

Polycaprolactone (PCL) scaffolds having macropores interconnected with micorpores are provided. Tissue grafts that include the PCL scaffold having therapeutic cells encapsulated within the macropores are also provided. Also provided are methods of making the PCL scaffold and the tissue graft, and methods of transplanting cells into an individual using the tissue graft.

The invention relates to the technical field of nerve injury repair, in particular to a spinal cord injury repair system based on ordered collagen scaffold carried cell transplantation combined with electroacupuncture stimulation application. The invention provides a spinal cord injury repairing system, which comprises a biological material support transplanting module, a cell inoculating module and a spinal cord injury repairing module, and the electro-acupuncture stimulation module is used for applying electro-acupuncture stimulation to acupuncture points after the biological material stent inoculated with the cells is transplanted to the spinal cord injury part. According to the system, electroacupuncture stimulation and biomaterial stent transplantation cells are combined for application, the microenvironment can be remarkably improved, survival, differentiation and function integration of the transplantation cells can be promoted, meanwhile, muscle atrophy and joint degeneration are relieved, an innovative treatment system is provided for spinal cord injury, and the system has high clinical feasibility and is worthy of popularization and application. Good application prospects are realized in the field of spinal cord injury repair.

Novel methods are disclosed for treating patients with Parkinson's disease and other primary and secondary parkinsonian disorders by improving cell engraftment. Treating patients with antihyperlipidemic drugs and / or CSF-1R antagonists before, during, and / or after transplantation of DA neurons improves cell viability, engraftment, proliferation, migration, or differentiation of the administered DA neurons. Methods are disclosed for pre-treating patients to improve engraftment of administered cells. Methods are disclosed for pre-treating patients to improve engraftment of administered progenitor cells.

An implantable membrane construct including a maximum pore size (MPS) less than 2 microns and opposing sides, each side of the construct having a surface roughness (Sa) greater than about 0.5 microns is disclosed. When the luminal surface of the implantable membrane construct has a surface roughness (Sa) greater than about 0.5 microns, mesenchymal cells do not form at the interface of the lumen and the first layer (i.e., luminal interface) such that the mesenchymal cells do not impede the flow of oxygen and nutrients to the graft cells (when implanted). When implanted, the outermost layer of the implantable membrane construct enables cellular penetration, vascularization, and anchoring of the construct. The implantable membrane construct includes single layer embodiments and multiple layer embodiments. Encapsulation devices utilizing the implantable membrane constructs to encapsulate biological entities (e.g., cells) into a patient are also provided.

An implantable membrane structure is disclosed that includes a maximum aperture (MPS) of less than 2 microns and opposing sides, each side of the structure having a surface roughness (Sa) of greater than about 0.5 microns. When the surface roughness (Sa) of the lumen surface of the implantable membrane structure is greater than about 0.5 microns, mesenchymal cells do not form at the interface of the lumen and the first side, i.e., the lumen interface, so that the mesenchymal cells do not hinder flow of oxygen and nutrients to transplanted cells (when implanted). When implanted, the outermost layer of the implantable membrane structure enables cell penetration, vascularization, and structural anchoring. The implantable membrane structure includes a single layer embodiment and a multi-layer embodiment. Encapsulation devices for encapsulating biological entities (e.g., cells) into a patient using implantable membrane structures are also provided.

The field of the invention encompasses synthetic chromosome compositions and methods that allow single cell spatiotemporal analysis in response to differentiation cues and labeling of transplanted cells to monitor the fate and function of such cells in the patient recipient.

The purpose is to provide a method for suppressing rejection by NK cells in cells or a tissue for transplantation. Provided is a method for producing cells or a tissue for transplantation, the method comprising a step for expressing, on the surface of cells for transplantation or cells constituting a tissue for transplantation, at least one membrane-type stimulating antibody specific to an inhibitory receptor for NK cells. Preferably, the method comprises a step of expressing a membrane-type stimulating antibody specific to each of one or more, for example, three or more, for example, four inhibitory receptors selected from the group consisting of NKG2A, KIR2DL1, KIR2DL3, KIR3DL1 and LILRB1. The present invention further provides pluripotent stem cells and T cells or progenitor cells thereof in which a gene encoding the membrane-type stimulating antibody is introduced or expressed. The present invention further provides an antibody specific to an inhibitory receptor for NK cells.

Nanoparticles, methods, and kits are provided for supplying nutrients and other therapeutic agents to transplanted cells. Nutrient deprivation is a significant factor which contributes to poor outcome of many cell transplants because cells receive insufficient nutrients until they are able to establish a functional microcirculation to support their metabolic and physiological needs after transplantation. Nanoparticles are provided for use in supplying nutrients and other therapeutic agents to transplanted cells to improve cell survival. Such nanoparticles can be used to supply nutrients and other factors to transplanted cells until the transplanted cells are able to develop a new microcirculation.

Provided herein are methods of inducing immune tolerance to graft cells in a human patient in need thereof comprising administering to the patient (i) the graft cells. (ii) a chimeric FasL protein conjugated to a hydrogel, and (iii) transient sirolimus.

The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.

The invention relates to a myocardial progenitor cell and drug double-loaded hydrogel biological material and application thereof, and particularly provides a biological material compound which comprises an organic compound, living cells and a loading material, and the organic compound can induce expression of protease. The compound is used in the treatment process of myocardial infarction (MI), the functionality of transplanted cells is improved, and effective repair and functional recovery of damaged myocardium are promoted.

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).

The present invention relates to the use of midbrain organoids in the preparation of a medicament for treating Parkinson's disease, wherein the midbrain organoids are derived from pluripotent stem cells and do not contain serotonergic neurons. The present invention discovers for the first time the therapeutic effect of midbrain organoids on Parkinson's disease, which has advantages such as high compatibility compared to the transplanted cells obtained by two-dimensional culture of iPSCs, and has advantages such as no ethical obstacles, sufficient sources, homogeneity, and no pollution compared to the grafts isolated from fetal ventral midbrain tissue.

The invention belongs to the technical field of regenerative medicine and cell therapy, and particularly relates to a CTLA4. FasL modified liver oval cell and bone marrow mesenchymal stem cell co-transplantation composition and application thereof in liver disease treatment. The invention provides a co-transplantation composition of CTLA4. FasL modified liver oval cells combined with bone marrow mesenchymal stem cells. The T cell rejection reaction is inhibited through the hexamer synergistic effect of the fusion protein CTLA4. FasL, and meanwhile the liver microenvironment is rapidly improved through the paracrine effect of BMSCs. Experiments prove that the composition significantly improves the transplanted cell colonization rate and the liver function recovery speed, and provides a new scheme for treatment of hepatic failure.

The present disclosure is related to compositions and systems for inducing immune tolerance for transplanted cells, organ, or tissues in a transplant recipient. Also provided herein are methods of making and methods of administering tolerizing vaccines / regimen or preparatory regimens.

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof. In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

To provide a bornavirus vector that improves the proliferative potential, engraftment efficiency, and expression of a target gene in transplanted cells, and further provide a recombinant virus comprising RNA encoded by the bornavirus vector, cells infected with the recombinant virus, and a pharmaceutical composition comprising the cells.SOLUTION: A bornavirus vector comprising a nucleic acid encoding a growth factor, a recombinant virus comprising RNA encoded by the bornavirus vector, cells into which the nucleic acid has been introduced by infection with the recombinant virus, and a pharmaceutical composition comprising the cells.SELECTED DRAWING: Figure 6

The invention discloses a cell composition and application thereof in preparation of a preparation for treating diabetes mellitus. The cell composition contains pancreatic duct stem cells and functional islet cells formed by chemically inducing the pancreatic duct stem cells to differentiate. According to the invention, rat pancreatic duct stem cells derived from adult rats and functional islet cells chemically induced in vitro are transplanted through hepatic portal veins in a combined manner, so as to treat STZ modeling rat diabetes mellitus. Functional islet cells can directly and timely play a role in reducing blood sugar after entering the body; meanwhile, the transplanted pancreatic stem cells can be continuously amplified and gradually differentiated in vivo to form functional islet cells, so that the hypoglycemic effect is further continuously achieved, and diabetes can be treated for a longer time. The invention provides a method for treating diabetes mellitus through cell transplantation of human beings and other animals, and the method has important theoretical significance and huge social application value and economic value.

Enhancing the fusion ability of transplant cells tends to arrest their proliferation in the production thereof, whereas promoting the proliferation of transplant cells tends to hinder their fusion at a transplantation site. Under such circumstances, the purpose of the present invention is to enable long-term engraftment of transplant cells regardless of concomitant use of immunosuppressants by endowing transplant cells with fusion ability and allowing the transplant cells to exert the fusion ability at a transplantation site at a desired time point, thereby overcoming the problem of graft failure and immune rejection resulting in loss of cells. The present invention provides a cell containing a cell-cell fusion gene as a foreign gene, wherein the cell-cell fusion gene is allowed to be expressed in the presence of an extracellular factor.

This disclosure relates to ligand - payload based drug delivery for cell therapy, and a drug delivery platform is disclosed herein that provides for flexible fine - tuning of cell therapy. In particular, an engineered fusion protein is conjugated to a high - affinity ligand carrying at least one drug payload that is internalized by the cells to be transplanted, to observe or modulate the effects of the transplanted cell therapy.

Disclosed herein are systems, devices, and method for implanting biological material in a subject in need thereof. The devices comprise a non-mechanically immune-isolating space defined by a protective, perforated frame and a placeholder disposed within the frame. The frame and plunger allow for vascularization to occur through the device. The plunger may be removed and therapeutic biological material comprised of a carrier matrix, tolerance inducing materials and therapeutic cells are deposited in the volume vacated by the plunger. The systems, devices, and methods allow for therapeutic deposition of transplanted cells without the need for long-term global immunosuppression.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and / or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and / or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

To provide a method for producing T cells for transplantation, by which T cells having an improved duration in vivo can be produced, to provide T cells having an improved duration in vivo, and to provide a pharmaceutical composition containing the T cells.SOLUTION: A method for producing a T cell for transplantation, comprising a step (A) of increasing an expression level of a nitric oxide synthase interacting protein in a T cell. There is also provided a T cell into which a nucleic acid having a function of improving an expression level of a nitric oxide synthase interacting protein is introduced.SELECTED DRAWING: None